Objective: Practice guidelines for the initial treatment of bipolar II (BP II) major depressive episode (MDE) recommend mood stabilizer (MS) monotherapy or combined MS plus antidepressant drug (AD) therapy. We hypothesized that initial AD monotherapy would be superior to MS monotherapy for BP II MDE with a low hypomanic switch rate. Methods: Bipolar II MDE patients were randomized to a 12-week open-label treatment with either venlafaxine monotherapy (n = 43) or lithium carbonate monotherapy (n = 40). The primary outcome measure was the 28-item Hamilton Depression Rating Scale (HAM-D 28). The secondary outcome measures included the Young Mania Rating Scale (YMRS), clinical global impressions severity and change ratings, and the proportion of patients classified as responder (with Q50% reduction in baseline HAM-D score) or as remitter (final HAM-D score, e8). Results: Thirty-four venlafaxine-treated patients (79.1%) and 15 lithium-treated patients (37.5%) completed the trial (P < 0.0005). Venlafaxine monotherapy produced a greater reduction in HAM-D 28 scores, with a difference in change of j6.57 points (95% confidence interval, j11.97 to j1.18) (P = 0.017) between treatment conditions. There was a greater proportion of venlafaxine-treated (vs lithium-treated) patients classified either as treatment responder (58.1% vs 20.0%; P < 0.0005) or as treatment remitter (44.2% vs 7.5%; P < 0.0005) for the HAM-D 28 scores. There was no significant increase in mean YMRS scores over time in the venlafaxine (vs lithium) treatment condition, and no significant increase in mean YMRS scores at any study visit compared with baseline for either treatment. Conclusions: Results from this study suggest that AD monotherapy with venlafaxine may be an effective initial therapy for BP II MDE with a low hypomanic switch rate. , by a preponderance of depressive episodes with a lifetime prevalence of at least 1 hypomanic episode lasting a minimum of 4 days. Bipolar II disorder is difficult to diagnose, often presents as a mixed hypomanic and depressive state, and frequently goes unrecognized. [2] [3] [4] 7, 8 It is diagnostically stable over time [9] [10] [11] and rarely evolves into bipolar I (BP I) disorder. [11] [12] [13] [14] [15] [16] [17] There is also evidence that BP II disorder is a distinct entity from BP I disorder based on genetic and biologic factors. 1, 11, [18] [19] [20] It is highly recurrent, with most illness time spent in depressive episodes. 1,21-24 As a result, it is associated with substantial morbidity and mortality. 22, [25] [26] [27] [28] [29] [30] [31] [32] Practice guidelines for the treatment of BP II major depressive episode (MDE) are largely empirical and based on the recommendations for treating BP I MDE. [33] [34] [35] [36] [37] [38] [39] [40] None have been based on controlled clinical trials, and none have endorsed the use of antidepressant drug (AD) monotherapy because of concerns of AD-induced mania. [41] [42] [43] [44] [45] The American Psychiatric Association 33,34 recommends that initial treatment of BP II MDE begins with mood stabilizer (MS) monotherapy or with the combination of MS and AD therapy (with the AD therapy administered at the lowest effective dose for the shortest time necessary). Another expert panel of psychiatrists recommends initiating MS monotherapy and avoiding AD monotherapy altogether, 37 with any previously established AD therapy tapered and discontinued within 12 weeks after remission. 37 In contrast, the Expert Consensus Panel for Bipolar Disorder 35 suggests that AD monotherapy may be considered in BP II MDE patients with a history of minimal hypomania. Other practice guidelines recommend starting MS monotherapy for mild to moderate BP II depression, and combine MS and AD therapy for more severe depressive symptoms. 38, 39 Finally, Dantzler and Osser 40 recommend bupropion as an initial therapy for BP II MDE, although this recommendation is not based on controlled prospective trials.
T he most common phenotypic expression of bipolar illness is bipolar II (BP II) disorder. [1] [2] [3] [4] [5] Initially described in 1976, 6 it is characterized in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (Text Revision [DSM-IV-TR]), by a preponderance of depressive episodes with a lifetime prevalence of at least 1 hypomanic episode lasting a minimum of 4 days. Bipolar II disorder is difficult to diagnose, often presents as a mixed hypomanic and depressive state, and frequently goes unrecognized. [2] [3] [4] 7, 8 It is diagnostically stable over time [9] [10] [11] and rarely evolves into bipolar I (BP I) disorder. [11] [12] [13] [14] [15] [16] [17] There is also evidence that BP II disorder is a distinct entity from BP I disorder based on genetic and biologic factors. 1, 11, [18] [19] [20] It is highly recurrent, with most illness time spent in depressive episodes. 1, [21] [22] [23] [24] As a result, it is associated with substantial morbidity and mortality. 22, [25] [26] [27] [28] [29] [30] [31] [32] Practice guidelines for the treatment of BP II major depressive episode (MDE) are largely empirical and based on the recommendations for treating BP I MDE. [33] [34] [35] [36] [37] [38] [39] [40] None have been based on controlled clinical trials, and none have endorsed the use of antidepressant drug (AD) monotherapy because of concerns of AD-induced mania. [41] [42] [43] [44] [45] The American Psychiatric Association 33, 34 recommends that initial treatment of BP II MDE begins with mood stabilizer (MS) monotherapy or with the combination of MS and AD therapy (with the AD therapy administered at the lowest effective dose for the shortest time necessary). Another expert panel of psychiatrists recommends initiating MS monotherapy and avoiding AD monotherapy altogether, 37 with any previously established AD therapy tapered and discontinued within 12 weeks after remission. 37 In contrast, the Expert Consensus Panel for Bipolar Disorder 35 suggests that AD monotherapy may be considered in BP II MDE patients with a history of minimal hypomania. Other practice guidelines recommend starting MS monotherapy for mild to moderate BP II depression, and combine MS and AD therapy for more severe depressive symptoms. 38, 39 Finally, Dantzler and Osser 40 recommend bupropion as an initial therapy for BP II MDE, although this recommendation is not based on controlled prospective trials.
Early studies of MS monotherapy did not show consistent antidepressant efficacy in mixed populations of BP I and II depressions. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] However, a 12-week prospective study of fluoxetine monotherapy in 839 MDE patients found a similar response rate among 89 BP II MDE patients compared with 89 age-and sex-matched unipolar patients (selected from the remaining 750 unipolar patients). 13 Moreover, in their study, symptoms suggestive of syndromal or subsyndromal hypomania occurred in only 3 (3.8%) of 80 BP II patients and in 2 (0.3%) of 661 unipolar patients. 13 A subsequent 6-week trial using venlafaxine monotherapy in 16 BP II and 26 unipolar MDE patients also found similar response rates among diagnostic groups with no reported hypomanic episodes. 52 More recently, we prospectively treated 37 BP II MDE patients with fluoxetine monotherapy for 8 weeks and found a remission rate of 48%. 14, 15 Three patients (7.34%) had a mild hypomanic episode that did not require discontinuation of treatment. In that study, mean Young Mania Rating Scale (YMRS) 53 scores did not significantly increase during fluoxetine monotherapy. 14, 15 We now present results from a prospective, randomized, open-label comparison of venlafaxine versus lithium monotherapy for BP II MDE. We hypothesized that venlafaxine monotherapy would be superior to lithium monotherapy with a similar hypomanic switch rate.
MATERIALS AND METHODS

Study Setting
The trial was conducted at the Depression Research Unit of the University of Pennsylvania Medical Center. The investigative site, established in 1966, is an outpatient clinical and research facility that examines approximately 500 new mood disorders patients and treats approximately 150 patients per year in clinical research studies.
Patient Selection
Outpatients 18 years and older, with a DSM-IV Axis I diagnosis of BP II disorder and current DSM-IV Axis I diagnosis of acute (<2 years) or chronic (Q2 years) MDE, were included. All patients had a baseline 17-item Hamilton Depression Rating Scale 54 (HAM-D 17) score of 18 or higher. Patients with a comorbid DSM-IV Axis I diagnosis other than MDE were not excluded from the study if the comorbid condition did not constitute the primary disorder. Patients were excluded if they had a history of mania or psychosis, substance abuse or dependence in the preceding 3 months, nonresponse to venlafaxine or lithium therapy within the current MDE, or had sensitivity to venlafaxine or lithium. Other exclusion criteria were the presence of an unstable medical condition, pregnancy or nursing, TSH level of 5 uIu/mL or higher, significant cardiac, hepatic, or renal disease, dementia, malignancy, or use of chemotherapy, concurrent AD, MS, neuroleptic, tranquilizer, or over-the-counter antidepressant preparation.
Procedures
Patients provided informed consent in accordance with the ethical standards of the institutional review board of the University of Pennsylvania. The study was conducted using the Principles of Good Clinical Practice Guidelines, with oversight monitoring by the local office of human research and by an independent data and safety monitoring board. Figure 1 displays the Consolidated Standards of Reporting Trials' flow diagram of patient enrollment in the study.
A psychiatric and medical history was obtained using the Structured Diagnostic Interview for DSM-IV format. 55 Physical examination and laboratory tests were performed, including blood cell count, electrolytes, glucose, hepatic enzymes, urea nitrogen, creatinine, and thyroid panel analysis, pregnancy test (in women), urinalysis, urine drug screen, and electrocardiography. Estimates of the number of prior depressive and hypomanic episodes were obtained using the Structured Diagnostic Interview for DSM-IV 55 as defined by the DSM-IV-TR criteria. In addition, the number of prior subsyndromal hypomanic (ie, hyperthymic) episodes lasting less than 4 days was estimated.
Structured ratings of the 28-item Hamilton Depression Rating Scale (HAM-D 28) and YMRS were obtained by a study physician or nurse. Symptom ratings were obtained with attribution as to the origin of the symptom. For example, insomnia could be recorded either as a depressive symptom on the HAM-D or as a hypomanic symptom on the YMRS. It could also be simultaneously recorded on both rating instruments as a mixed depressive and hypomanic symptom if the evaluator attributed the insomnia to the presence of both depression and hypomania. This rating method sometimes resulted in baseline YMRS scores that were above zero.
Treatment
Patients discontinued their previously established ineffective or partially effective psychotropic drug therapy before randomization to treatment in the study. Patients who had a baseline HAM-D 17 score of 18 or higher were randomized to open-label monotherapy with either venlafaxine or lithium. Efficacy and safety measures were obtained at baseline and at study weeks 1, 2, 4, 6, 8, 10, and 12. Uniformity of treatment procedures was achieved using a structured clinical management format. 56 Venlafaxine monotherapy was initiated at 37.5 mg/d and increased to 75 mg/d during the first week of treatment. The dose was titrated upward in 37.5-or 75-mg increments every week, to a maximum dosage of 375 mg/d by week 4 of treatment. This dose was maintained for an additional 8 weeks. The venlafaxine dose could be reduced to a minimum of 37.5 mg/d, depending on tolerability. Patients unable to tolerate a dose of 37.5 mg/d discontinued participation in the trial. Venlafaxine was administered on a once-or twice-daily basis. 52 Lithium dosing was initiated at 600 mg/d for 1 week, and a serum lithium level was obtained. Based on tolerability and a minimum lithium level of 0.5 mmol/L, the dose of lithium was increased to 900 mg/d during the second week of treatment. This process was then repeated until a steady-state lithium level of 0.5 to 1.5 mmol/L was achieved at week 4 of therapy, and then maintained for an additional 8 weeks. Lithium 300-mg capsules were administered on a once-or twice-daily basis up to 900 mg/d, and twice daily at doses exceeding 900 mg/d. Patients who were unable to maintain a minimum serum lithium level of 0.5 mmol/L were discontinued from the trial. Serum lithium levels were obtained as close as possible to 12 hours after the preceding dose of lithium.
Concomitant therapy with zolpidem 5 to 10 mg, zaleplon 5 to 20 mg, or trazodone 25 to 75 mg was permitted for severe insomnia.
Outcome Measures
The primary outcome measure is the HAM-D 28 (with embedded HAM-D 17 and HAM-D 17 atypical symptom [HAM-D 17-R]) rating. 57 Secondary outcome measures included change in YMRS, Clinical Global Impressions-Severity (CGI/S) and Change (CGI/C) scores, 58 and the proportion of responder (with Q50% reduction in baseline HAM-D score) and remitter (final HAM-D score, e8) patients.
Sample Size Justification
The study was powered to detect a difference in response rates of 60% (for venlafaxine) versus 30% (for lithium) based on a 2-group W 2 test with a 2-sided significance level of 0.05. The number of subjects needed to distinguish between these response rates with 80% power was 42 per group.
Statistical Procedures
Initial analyses were descriptive and included means, medians, ranges, SD, and 95% confidence interval (CI). Sexspecific analyses were also conducted because females are thought to have a higher risk for AD-induced hypomania. 59, 60 Box plots were constructed to compare change over time between treatment conditions and to verify that the change was linear. Overlaid individual-level plots of outcomes versus time were assessed using the xtline procedure in Stata 9.1.
Primary comparisons implemented quasi-least squares 61 with the xtqls procedure for Stata 9.1. 62 Quasi-least squares analysis is based on generalized estimating equations and, similarly, adjusts for the correlation between repeated measurements on the subjects by specifying a working correlation structure of the pattern of association for measurements on each subject. Quasi-least squares analysis was applied to allow for implementation of the Markov correlation structure that models the correlation between repeated measurements y ij and y ik from patient i at time t ij and t ik as Corr (y ij , y ik ) = ! |t ij jt ik | . This structure was biologically plausible because it forced the correlation between measurements to be smaller when they were measured further apart in time. 62 It also allowed for unequal spacing of measurements in time, which can occur in clinical trials.
A regression model for the expected outcome value for subject i at visit j was used to test the primary hypothesis that change in HAM-D 28 (and other outcome) scores differed significantly between treatment conditions: 
Change over time differed significantly between conditions if " 4 differed significantly from 0, with a greater reduction for venlafaxine if " 4 < 0. The primary hypothesis was therefore tested via the null hypothesis, H 0 : " 4 = 0 and by assessing whether " 4 < 0. We also estimated the difference in change over time between conditions (77 " 4 ) with 95% CI for 77" 4 .
Regression model (1) was also used to examine the change for secondary outcome measures. Fisher exact test was used to compare the proportion of responder and remitter between treatment conditions. In addition, the proportions of patients (with 95% CI) with YMRS cutoff scores of 8 or higher and 12 or higher were computed in each treatment group and were compared using Fisher exact test. In addition, the t test and Wilcoxon rank sum test were used to compare the YMRS scores between treatment conditions at each measurement occasion. Quasi-least squares regression models were modified to include demographic and clinical variables to assess whether results were sensitive to the adjustment for these variables.
Finally, we conducted a sensitivity analysis because of the presence of significant differences between the treatment groups at baseline whereby the lithium-treated group had more prior hypomanic episodes, more prior MDEs, an earlier age of illness onset, and longer current MDE duration. We therefore modified the regression models described previously to include these additional factors.
RESULTS
Enrollment
Of 84 patients enrolled in the trial, 83 had a baseline study visit and at least 1 postbaseline outcome evaluation: 43 on venlafaxine and 40 on lithium. One patient (1.2%) was a screen failure and did not have a baseline visit. Thirty-three patients (39.8%) discontinued treatment before completing the trial: 11 for lack of efficacy, 13 for adverse events, 2 for noncompliance, and 7 who withdrew consent and were lost to follow-up.
Demographic data from 84 patients included: 48 (57%) women; 69 (82.1%) white, 7 (8.3%) African American, 2 (2.4%) Asian, 3 (3.6%) Hispanic, and 3 (3.6%) other. Mean There was a greater proportion of venlafaxine-treated (vs lithium-treated) patients classified as responder: HAM-D Finally, we conducted a sensitivity analysis because of the presence of significant differences between the treatment groups at baseline whereby the lithium-treated group had more prior hypomanic episodes, more prior MDEs, had an earlier age of illness onset, and had longer current MDE duration. We modified the regression models to include these additional factors. The results were unchanged.
Hypomanic Symptoms
The median and mean (SD) YMRS scores at baseline (before randomization) for all patients were 0 and 0.71 (1.93), respectively. The median YMRS scores at each week after randomization for venlafaxine versus lithium were 0 versus 0, whereas the mean (SD) YMRS scores for venlafaxine versus lithium are displayed in Table 3 . A t test and Wilcoxon rank sum test were used to compare the YMRS scores between treatment conditions at each measurement occasion. Mean YMRS scores were slightly higher at all weeks for the lithium-treated versus the venlafaxine-treated group, except for week 6 when the mean YMRS score was slightly higher in the venlafaxine-treated group. There was no significant difference in mean YMRS scores at any week, except for baseline when the YMRS scores were significantly higher for the lithium-treated group (P = 0.02). Figure 3 displays overlaid individual-level plots of YMRS scores over time for each treatment condition. This figure also displays the horizontal line of the conservative YMRS cutoff value of 8 or higher for subsyndromal hypomanic and hypomanic symptoms. Only 2 patients (2.5%; 95% CI, 0.3 to 8.6) had a YMRS score of 8 or higher on at least 1 study visit: 1 patient on venlafaxine (2.4%; 95% CI, 0.06 to 12.6), and 1 patient on lithium (2.6%; 95% CI, 0.06 to 13.5) (P = 0.99).
Using a slightly less conservative YMRS cutoff score of 12 or higher, only 1 venlafaxine-treated patient (2.4%) and no lithium-treated patient had this score (P = 0.99) (note that the venlafaxine-treated patient with a YMRS score Q8 was the same subject with the YMRS score Q12). Quasi-least squares analysis indicated that there was no significant increase in YMRS scores over time with venlafaxine (vs lithium), and no significant increase in YMRS scores at any study visit (vs baseline) for either treatment condition. The estimated difference in the overall change in YMRS score between treatment conditions was 77 " 4 = 0.02 (95% CI, j0.71 to 0.76) greater for venlafaxine versus lithium. This represents a difference between treatments in YMRS change scores from baseline to week 12 of 0.02, which is clinically and statistically insignificant. Finally, bivariate and quasileast squares analyses failed to identify any demographic or clinical variable associated with change in YMRS ratings.
Missing Data
There were 83 subjects at baseline, 81 at week 1, 76 at week 2, 73 at week 4, 68 at week 6, 64 at week 8, 56 at week 10, and 49 at week 12. The mean number of measurements per subject was 5.5 (median, 7). We used intent-to-treat with a regression model that allowed for a variable number of observations, so that no subject was dropped from the data analysis. Secondary analyses were used to assess the sensitivity of our findings to missing data by replacing the missing value(s) on each subject with baseline value(s) in the regression analyses. There was no difference between the 2 approaches (with the exception that venlafaxine efficacy was more pronounced for the imputed data).
Safety
Thirteen patients (15.7%) withdrew from treatment due to an adverse event. There was 1 serious adverse event in the lithium-treated group, which was judged to be unrelated to drug therapy. Table 4 displays the frequency of reported and elicited adverse events from 83 patients who completed the baseline evaluation. Most adverse events were rated as mild or moderate in intensity. There were no clinically meaningful changes in vital signs, physical findings, or laboratory values. There were no cases of lithium toxicity. Finally, there were 2 occurrences of hypomania during venlafaxine and 1 occurrence with lithium. Two venlafaxine-treated patients and 1 lithium-treated patient received concurrent treatment of insomnia with zolpidem or zaleplon, and 1 venlafaxine-treated and 3 lithium-treated patients received trazadone for insomnia. Finally, 1 venlafaxine-treated patient discontinued treatment of hypomania, and 1 patient discontinued lithium treatment of increased suicidal ideation.
DISCUSSION
Despite a paucity of controlled clinical data supporting the initial use of MS monotherapy for BP II MDE, it remains the most frequently recommended therapy. [33] [34] [35] [36] [37] [38] [39] To date, however, there are few controlled clinical trials supporting this strategy. Early studies found tricyclic antidepressant (TCA) monotherapy (or combined lithium plus TCA therapy) to be superior to lithium monotherapy. 46, 63 These studies generally included mixed BP I and BP II MDE populations. As a result, conclusions about the relative efficacy of MS versus AD monotherapy for BP II MDE remain limited. A recent 12-month efficacy trial comparing 2 MS monotherapies, lithium versus carbamazepine, in BP I and BP II MDE patients found a modest (33%) response rate for both therapies, with neither treatment reducing the time spent in depression. 51 Although newer MS agents may have improved antidepressant efficacy, most studies have focused exclusively on BP I disorder. [64] [65] [66] [67] [68] [69] [70] [71] The recommendation for using initial MS monotherapy for BP II MDE derives principally from results of BP I MDE studies of TCA-induced manic switch episodes. [41] [42] [43] [44] 46 Estimates of AD-induced manic and hypomanic switch rates in BP disorder have ranged either from 2% to 70% and are largely based on observations with TCAs in BP I MDE patients 42, 46, [72] [73] [74] [75] [76] [77] [78] [79] or from naturalistic or chart review studies of mixed BP I and BP II populations. 42, 66, 75 In contrast, patients with BP II disorder may be less likely to have AD-induced hypomania. [13] [14] [15] [16] [17] [76] [77] [78] [79] [80] [81] [82] In 1 prospective study, Kupfer et al 78 found that BP II patients were no more likely than unipolar patients to develop hypomania during AD monotherapy.
More recently, we examined the efficacy and hypomanic switch rate of fluoxetine monotherapy for 8 weeks in 37 BP II MDE patients. 14, 16 Fourteen patients (38%) responded to treatment with a final HAM-D score of 9 or lower. We found no change in mean YMRS scores at any study visit compared with baseline (P = 0.93). Only 3 patients (8.1%) had a YMRS score of 8 or higher at 2 study visits, and only 3 patients (8.1%) met DSM-IV criteria for a brief hypomanic episode. In a separate 6-week dose-escalation study of venlafaxine monotherapy up to 225 mg/d in 17 BP II and 31 unipolar MDE patients, venlafaxine resulted in a significant reduction in HAM-D 17 scores in both patient groups (P < 0.001), with no difference in efficacy between groups. We observed no hypomanic episodes.
Results from the present study extend these earlier observations and suggest that initial AD monotherapy with venlafaxine may be an effective treatment of BP II MDE with a low hypomanic switch rate. We observed a greater reduction in HAM-D 28, HAM-D 17, HAM-D 17-R, and CGI/S ratings during venlafaxine (vs lithium) monotherapy. We also found a greater proportion of treatment responder and remitter patients with venlafaxine monotherapy. In contrast to the expected high frequency of hypomanic and subsyndromal hypomanic symptoms during venlafaxine monotherapy, we observed no significant increase in YMRS scores over time with either venlafaxine or lithium monotherapy (P = 0.85).
Other investigators have reported a higher frequency of hypomanic symptoms during venlafaxine therapy. For example, Vieta et al 83 reported a higher manic switch rate with venlafaxine compared with paroxetine, whereas Leverich et al 84 observed a greater frequency of hypomanic symptoms during venlafaxine treatment compared with sertraline and bupropion. However, these studies were either limited to patients with BP I disorder 83 or included a mixed population of BP I, BP II, BP not otherwise specified, and schizoaffective patients. 84 In addition, the studies of Altshuler et al 82 and Leverich et al 84 had several methodological shortcomings, including unbalanced dispensing of bupropion that may have led to outcome bias against venlafaxine. Moreover, these studies did not specifically compare AD with MS monotherapy, and all patients were taking concurrent MS and/or atypical antipsychotic therapy.
Several caveats should be considered in the interpretation of the present findings. For example, our study did not use a patient-recorded daily chronorecord for identifying ultrashort affective episodes. It is possible that we missed the presence of subsyndromal hypomanic or episodes that occurred between study visits. However, the estimated difference in change in YMRS scores across all study visits was only 0.02 (95% CI, j0.98 to 1.03) for venlafaxine (vs lithium) monotherapy. Nevertheless, the failure to find a difference in YMRS scores over time between treatment conditions is not proof that a difference did not exist. In addition, we would note that although this study was powered to detect differences in response rates between treatment conditions, it was not powered to detect differences in hypomanic switch rates between treatments. In this regard, larger sample sizes would have been required to detect a significant difference in hypomanic switch rates, if these were assumed to be small and similar between the 2 treatment conditions. Nevertheless, the observed treatment group difference in change in YMRS scores of 0.02 for 12 weeks during venlafaxine monotherapy is clinically and statistically insignificant.
It is possible that the frequency of venlafaxine-induced hypomanic symptoms may have been higher had a longer treatment duration been used. However, observations from our prior fluoxetine and venlafaxine monotherapy studies indicated that most treatment-emergent hypomanic symptoms occurred before week 6 of treatment, if at all. [13] [14] [15] [16] [17] 52 The lack of a placebo control group placed constraints on our ability to assess the true comparative efficacy of venlafaxine versus lithium monotherapy, as well as our ability to determine the true comparative hypomania switch rate during venlafaxine and lithium treatments. It is possible that the low frequency of hypomanic symptoms during venlafaxine monotherapy represents the background frequency in patients with BP II MDE, rather than true drug-induced hypomanic symptoms. Whereas Vieta et al 83 and Leverich et al 84 found higher manic symptom rates with venlafaxine in BP I MDE patients, other investigators have reported a low incidence of drug-induced hypomanic symptoms during venlafaxine monotherapy in patients with BP II disorder 82, 85 and have suggested that venlafaxine may act as an MS in some BP II patients. 85, 86 It is possible that a slower dose titration of lithium (vs venlafaxine), because of the need to achieve therapeutic lithium levels, may have disadvantaged lithium, and that this difference resulted in a superiority of venlafaxine treatment. However, patients in both treatment conditions had a gradual dose increase based on symptom change and tolerability. Although the mean (SD) maximum dose of venlafaxine was 186 (92) mg/d, the maximum lithium dose of 966.24 (410.9) mg/d was limited by a maximum serum lithium level of 1.5 mmol/L. Thus, it is possible that the modest efficacy of lithium was an artifact that may have disappeared with higher lithium doses. However, we would also note that a mean (SD) daily lithium dose of 966.2 (410.9) mg and a mean (SD) serum lithium level of 0.64 (0.265) mmol/L may also have been responsible for the higher treatment discontinuation rate in the lithium (vs venlafaxine) treatment condition. Maximized lithium dosing was generally limited by adverse events. We would also note that standard dosing of venlafaxine or lithium for the initial treatment of BP II MDE has not yet been established, and the benefit of long-term AD or MS monotherapy for BP II disorder remains uncertain.
It is possible that the modest efficacy of lithium monotherapy was an artifact of the limited sample size and 12-week treatment duration, and that this finding may have disappeared with a larger sample size treated for a longer period. We would note, however, that this study was powered to detect differences in response rates of the HAM-D 28 during short-term monotherapy. The relative benefit of this treatment strategy during long-term, relapse-prevention therapy remains to be established.
Finally, we acknowledge the shortcoming of a randomized open-label study design, and note that this limitation may have introduced a study bias. We submit, however, that this methodological limitation does not invalidate the present results that support observations reported from earlier double-blind studies of BP II MDE therapy. [14] [15] [16] [17] 77, 82, 84, 86 Moreover, we are unaware of any other adequately powered, prospective randomized studies to date comparing AD to MS monotherapy for BP II MDE. We would certainly recommend that future clinical trials of AD versus MS monotherapy for BP II MDE use a double-blind placebocontrolled design.
CONCLUSIONS
This study compared venlafaxine monotherapy with lithium monotherapy for the initial treatment of BP II MDE. We hypothesized that venlafaxine monotherapy would be superior to lithium monotherapy with a similar hypomanic switch rate. We observed a significantly greater reduction of depressive symptoms during venlafaxine versus lithium monotherapy. There was also a significantly greater proportion of patients classified as treatment responder or remitter during venlafaxine monotherapy in an analysis that treated subjects who dropped out before the end of the study as nonresponders. These observations suggest that venlafaxine monotherapy may be a safe and effective initial treatment of BP II MDE with a low frequency of hypomanic symptoms.
